NCT03255096 - A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 28, 2017

Primary Completion Date

July 3, 2019

Study Completion Date

July 3, 2019

Conditions

Diffuse Large B-cell LymphomaHigh-Grade B-cell Lymphoma

Interventions

DRUG

RO6870810

RO6870810 subcutaneously (SC) at dose of 0.30, 0.45, or 0.65 milligram per kilogram (mg/kg) on Days 1-14 of 21-day cycles.

DRUG

Venetoclax

Venetoclax tablets orally at dose of 400 mg once daily (QD) continuously for 21 days.

DRUG

Rituximab

Rituximab intravenously (IV) at dose of 375 mg/m\^2 weekly during the first 21-day cycle (C1) and on day 1 of each cycle thereafter.

Trial Locations (9)

Rigshospitalet; Hæmatologisk Klinik, København Ø

Peter MacCallum Cancer Centre-East Melbourne, Melbourne

Weill Cornell Medical College, New York

START Madrid-FJD, Hospital Fundacion Jimenez Diaz, Madrid

Levine Cancer Institute - Blythe, Charlotte

City of Hope National Medical Center, Duarte

Stanford Cancer Center, Stanford

Hospital de la Santa Creu i Sant Pau; Servicio de Hematologia, Barcelona

Hospital Duran i Reynals; Servicio de Hematologia, Barcelona

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY